FindTrial
Sign In

Managed Access Program for Momelotinib in Myelofibrosis

Managed Access Program for Momelotinib in Patients With a Diagnosis of Intermediate or High-risk Myelofibrosis (MF), Including Primary Myelofibrosis (PMF) or Secondary Myelofibrosis (Post- Polycythemia Vera/ Essential Thrombocytopenia (PV/ET)), With Anaemia

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05582083
Enrollment
Unknown
Registered
2022-10-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelofibrosis, Primary Myelofibrosis

Keywords

Momelotinib, GSK3070785

Brief summary

Compassionate use access to Momelotinib/GSK3070785 for eligible participant with diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia.

Interventions

DRUGMomelotinib

Momelitinib available as tablets.

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Written informed consent can be obtained from the patient or legally authorised representative as per local regulations * Diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia * 18 years or older (at the time consent is obtained) * The patient is willing to abide by the contraception requirements. * No known hypersensitivity to momelotinib, its metabolites, or any of the formulation excipients

Exclusion criteria

* Pregnant or breastfeeding female

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026